Harlow Packaging: Covenant Headroom That Depends on the Definition of EBITDA
Harlow Packaging is seeking a $120 million dividend recapitalisation funded with a new term loan. Its revolving credit facility tests net leverage at 5.0x, defined as net debt divided by trailing-twelve-month 'Consolidated EBITDA'. Reported EBITDA is $180 million. The company's calculation adds back $25 million of run-rate cost synergies from a 20X3 acquisition, $10 million of 'non-recurring' restructuring and $6 million of stock-based compensation. Net debt is $880 million. The indenture permits add-backs for synergies expected within 24 months, capped at 15% of EBITDA before add-backs, and permits equity cures. Harlow has drawn $60 million of its revolver in each of the last two quarters and paid a special dividend of $90 million last year. Management forecasts EBITDA of $210 million next year.
1. Compute covenant leverage under the issuer's definition and under a conservative credit definition, and state the headroom in dollars under each.
Read the worked answer
Issuer definition. EBITDA = 180 + 25 + 10 + 6 = $221m Net leverage = 880 / 221 = 3.98x Headroom to 5.0x = (5.0 × 221) − 880 = $225m of additional net debt.
Conservative credit definition.
- Synergies: permitted, but capped at 15% of EBITDA before add-backs = 0.15 × 180 = $27m, so the $25m requested passes the cap. Keep 25.
- Restructuring labelled 'non-recurring': in a company that has taken charges in consecutive periods, the label is not evidence of non-recurrence. Exclude the $10m unless the lender has documented a specific, finite programme with a completion date.
- Stock-based compensation: a real economic cost that dilutes shareholders and is paid in lieu of cash. Exclude the $6m add-back. EBITDA = 180 + 25 = $205m Net leverage = 880 / 205 = 4.29x Headroom = (5.0 × 205) − 880 = $145m.
The gap matters. The two definitions differ by $80m of debt capacity on identical cash flows. In a downside case where EBITDA falls to $160m, the conservative definition gives EBITDA of 160 + 24 = $184m and leverage of 880 / 184 = 4.78x - still inside, but the issuer definition would show 3.9x and conceal the deterioration.
2. Test the pro forma position after the $120m recapitalisation, including a stress case, and explain how an equity cure would change the picture.
Read the worked answer
Pro forma, base case. Net debt becomes 880 + 120 = $1,000m. Synergy cap is unchanged because it is set on EBITDA before add-backs.
- Issuer: 1,000 / 221 = 4.52x - 0.48x of headroom.
- Conservative: 1,000 / 205 = 4.88x - 0.12x of headroom, i.e. roughly $25m of EBITDA deterioration before breach.
If management's $210m forecast is achieved. Conservative EBITDA = 210 + 25 = $235m (assuming the synergies are realised) → 1,000 / 235 = 4.26x. Comfortable if the forecast holds. The investment case therefore rests almost entirely on delivery of synergies and growth at the same time as the balance sheet is being levered.
Stress case. EBITDA flat at $160m (a 20% decline, plausible in packaging in a volume downturn): conservative EBITDA = 184 → 5.43x, a breach. Because the new debt is structurally senior and secured, the lender's recovery depends on enterprise value, not on the covenant.
Equity cure. The indenture allows the sponsor to inject equity and have it counted as EBITDA (or net debt reduced) to cure a breach. Consequences the analyst must weigh:
- It buys time but does not fix the business; each cure typically consumes one of a limited number of permitted cures (often twice over the life of the facility and not in consecutive quarters).
- A cure that is counted as EBITDA flatters the metric; a cure that pays down debt is cleaner.
- Lenders should price the option value of the cure into the spread rather than treating the covenant as a hard trigger.
3. What do the revolver draws, the special dividend and the quality of the add-backs tell you about the credit, independent of the ratio?
Read the worked answer
Revolver draws. Drawing $60m in each of the last two quarters and keeping it drawn is a liquidity signal. Revolvers are cheap insurance; a company that uses one for working capital is funding operations with short-term, callable money. At refinancing, the lender can refuse to renew, and the drawn amount becomes a bullet.
Special dividend of $90m followed by a $120m recap. Management is extracting equity ahead of a leveraged transaction. This is a transfer of value from creditors to shareholders, and it typically precedes deteriorating credit quality rather than following it. The analyst should ask what the sponsor's remaining equity cushion is, and whether the recap is a prelude to a sale or an exit.
Add-back quality.
- Synergies: permitted but unproven; cap them and monitor realisation against the 24-month window.
- 'Non-recurring' restructuring that recurs: treat as operating cost.
- Stock-based compensation: a genuine cost of the business, excluded only because it is non-cash. Adding it back overstates cash available for debt service. A useful discipline is to compute EBITDA on the indenture definition and on a cash basis, and to require that the two converge over time.
Assessment. Leverage under the issuer definition looks investment-grade-adjacent at 3.98x. On a conservative basis, with negative free cash flow implied by the revolver draws, a special dividend and a fresh recap, the credit is better characterised as a leveraged borrower with thin headroom, weak documentation on add-backs and a management team prioritising distributions over deleveraging. That view should drive the spread demanded, not the 3.98x.